{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 460779595
| IUPAC_name = 3-(1-benzyl-4-piperidyl)-3-phenylpiperidine-2,6-dione
| image = Dexetimide.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|dexetimide}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK = <!-- GSL         / P       / POM / CD -->
| legal_US = <!-- OTC                   / Rx-only  -->
| legal_status =  
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 21888-98-2
| ATC_prefix = N04
| ATC_suffix = AA08
| PubChem = 30843
| IUPHAR_ligand = 354
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB08997
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 28615
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 43477QYX3D
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03711
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1908364

<!--Chemical data-->
| C=23 | H=26 | N=2 | O=2 
| molecular_weight = 362.465 g/mol
| smiles = O=C2NC(=O)CCC2(c1ccccc1)C4CCN(Cc3ccccc3)CC4
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C23H26N2O2/c26-21-11-14-23(22(27)24-21,19-9-5-2-6-10-19)20-12-15-25(16-13-20)17-18-7-3-1-4-8-18/h1-10,20H,11-17H2,(H,24,26,27)/t23-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = LQQIVYSCPWCSSD-HSZRJFAPSA-N
}}

'''Dexetimide''' (brand name '''Tremblex''') is a [[piperidine]] [[anticholinergic]]. It is a [[muscarinic acetylcholine receptor|muscarinic]] [[receptor antagonist|antagonist]] that is used to treat [[Parkinsonism|drug induced parkinsonism]]. Dexetimide was discovered at [[Janssen Pharmaceutica]] in 1968.<ref>{{Cite journal 
| last1 = Dom | first1 = R. 
| last2 = Van Lommel | first2 = R. 
| last3 = Baro | first3 = F. 
| title = A quantitative study of neuroleptic-induced extrapyramidal symptoms and their response to dexetimide, a potent and long-acting antiparkinsonian agent 
| journal = Acta Psychiatrica Scandinavica 
| volume = 47 
| issue = 4 
| pages = 399–410 
| year = 1971 
| pmid = 4947805
 | doi=10.1111/j.1600-0447.1971.tb03697.x
}}</ref><ref>{{Cite journal 
| last1 = Huygens | first1 = H. 
| last2 = Vereecken | first2 = J. L. 
| last3 = Tanghe | first3 = A. 
| title = Dexetimide (R 16470) in the control of neuroleptic-induced extrapyramidal side-effects. Its prophylactic value and duration of action 
| journal = Psychiatria, neurologia, neurochirurgia 
| volume = 76 
| issue = 4 
| pages = 251–259 
| year = 1973 
| pmid = 4581374
}}</ref>

== References ==
{{Reflist}}

{{Antiparkinson}}
{{Muscarinic acetylcholine receptor modulators}}

[[Category:Muscarinic antagonists]]
[[Category:Piperidines]]
[[Category:Glutarimides]]
[[Category:Janssen Pharmaceutica]]
[[Category:Belgian inventions]]


{{nervous-system-drug-stub}}